Cubist Pharmaceuticals

NASDAQ: CBST
Source: ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in...
Source: ThinkstockThe world of biotech investing is always a difficult one. Often a binary event, such as a U.S. Food and Drug Administration (FDA) approval or a life-saving capital raise is the...
U.S. equity markets opened sharply lower again this morning, but this time reacting to yesterday’s comments by Fed Chairman Ben Bernanke that the Fed could slow its bond purchases in the next few...
These are the top analyst upgrades, downgrades and initiations from select Wall Street research calls on Friday, May 24, 2013. They include Cubist Pharmaceuticals, Marvell Technology and Procter...
Source: ThinkstockThe world of biotech investing is always a difficult one. Often a binary event, such as U.S. Food and Drug Administration (FDA) approval or a life-saving capital raise, is the...
Investors and traders seem to be constantly looking for fresh research ideas that will lead to higher income or more profits. 24/7 Wall St. reviews many fresh research calls each morning to find...
Source: ThinkstockThe world of biotech investing is always a difficult one. Often a binary event, such as a Food and Drug Administration (FDA) approval or a life-saving capital raise is the...
Investors and traders are constantly looking for fresh research ideas from Wall Street that will lead to higher income or more profits. We review many fresh research calls to find great ideas from...
U.S. equity markets opened very slightly higher this morning but it was all downhill from there. The U.S. jobs report from ADP came in weaker than expected and cast a shadow of Friday’s report on...
Source: Jon OggInvestors and traders generally stay on the lookout for new ideas that will generate positive returns or income for their portfolio. 24/7 Wall St. looks over numerous research calls to...
Source: ThinkstockBig biotech had a stellar 2012. In 2013, though, the large biotech companies may be dwarfed in performance by the smaller players in the $1 billion to $5 billion range. If you look...
Source: Thinkstock24/7 Wall St. is looking for the next great biotech stocks for 2013 after great gains have been seen in 2012. If you look at the consensus price targets from analysts for the coming...
The three major U.S. stock indexes opened higher this morning following the report on new jobless claims, which rose by 369,000, less than the expected 375,000 (our coverage here). In Europe, GDP in...
Source: Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall St. research calls this Thursday.Akamai Technologies Inc. (NASDAQ: AKAM) raised to Outperform at...
The three major US stock indexes opened lower this morning following on softness in European markets and a mixed close in the Asian markets. There has been little data for investors to chew on over...